Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: gg cox who wrote (13666)	10/1/2004 12:48:03 PM
From: Tom Johnson	of 14101

And the CBC as well........ Dimethaid shares soar on Vioxx fallout Last Updated Fri, 01 Oct 2004 11:23:06 EDT TORONTO - Shares of Dimethaid Research jumped more than 60 per cent Friday as investors bet that its anti-arthritis medication will benefit from the recall of Vioxx from the market. Dimethaid stock (TSX:DMX)was up 29 cents to 75 cents in heavy morning trading. Vioxx sales were worth $2.5 billion US yearly to Merck On Thursday, Merck withdrew Vioxx from sale after clinical trials showed that users were more likely to suffer heart attacks or strokes. Dimethaid makes Pennsaid, an anti-arthritis lotion. Within hours of Merck's withdrawal of Vioxx, Dimethaid had put out a news release that noted that a recent trial of Pennsaid lotion showed that it has an "overall better safety profile than pills containing the same active ingredient." The company said the trial (which it sponsored) also showed that Pennsaid worked "as well as the maximum daily dose of comparable oral medication at relieving knee osteoarthritis symptoms." Dimethaid is under new management. Last week, dissident shareholders succeed in ousting the previous board and CEO in a dispute over the direction of the company. The previous management was trying to position Dimethaid as an integrated pharmaceutical company. The current management wants to focus the company on biotech research and development and leave the marketing to third parties. Merck shares, which were hammered 27 per cent lower on Thursday, clawed back a bit of that loss Friday. They were up 86 cents US to $33.86 US. Written by CBC News Online staff Copyright ©2004 Canadian Broadcasting Corporation - All Rights Reserved

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next